Recent Posts
- Third-generation inhibitors targeting EGFR T790M mutation in advanced NSCLC
- Osimertinib Given as First-Line Treatment May Alter Biology of EGFR-Mutated NSCLC
- Osimertinib approved in EU as first-in-class treatment for NSCLC
- Osimertinib Given as First-line Treatment May Alter Biology of EGFR-Mutated Non-Small-Cell Lung Cancer
GLOBAL MARKETING PARTNER
Beacon Medicare Limited
9/B/2,Toyenbee Circular Road,
Motijheel,Dhaka-1223, Bangladesh
Phone: +880-2-57165371/79
Fax: +880 2-8870109
Web: beaconmedicare.com.bd